Cargando…
Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy
Plasminogen activator inhibitor-1 (PAI-1) has a cardioprotective function in mice by repressing cardiac fibrosis through TGF-β and plasminogen-mediated pathways. In addition it is known to be involved in the recruitment and polarization of monocytes/macrophages towards a M2 phenotype in cancer. Here...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801308/ https://www.ncbi.nlm.nih.gov/pubmed/33432417 http://dx.doi.org/10.1007/s00395-020-00840-w |
_version_ | 1783635548716400640 |
---|---|
author | Baumeier, Christian Escher, Felicitas Aleshcheva, Ganna Pietsch, Heiko Schultheiss, Heinz-Peter |
author_facet | Baumeier, Christian Escher, Felicitas Aleshcheva, Ganna Pietsch, Heiko Schultheiss, Heinz-Peter |
author_sort | Baumeier, Christian |
collection | PubMed |
description | Plasminogen activator inhibitor-1 (PAI-1) has a cardioprotective function in mice by repressing cardiac fibrosis through TGF-β and plasminogen-mediated pathways. In addition it is known to be involved in the recruitment and polarization of monocytes/macrophages towards a M2 phenotype in cancer. Here, we investigated the expression of PAI-1 in human dilated cardiomyopathy (DCM) and inflammatory dilated cardiomyopathy (DCMi) and its effect on cardiac fibrosis and macrophage polarization. We retrospectively analyzed endomyocardial biopsies (EMBs) of patients with DCM or DCMi for PAI-1 expression by immunohistochemistry. Furthermore, EMBs were evaluated for the content of fibrotic tissue, number of activated myofibroblasts, TGF-β expression, as well as for M1 and M2 macrophages. Patients with high-grade DCMi (DCMi-high, CD3(+) lymphocytes > 30 cells/mm(2)) had significantly increased PAI-1 levels compared to DCM and low-grade DCMi patients (DCMi-low, CD3(+) lymphocytes = 14–30 cells/mm(2)) (15.5 ± 0.4% vs. 1.0 ± 0.1% and 4.0 ± 0.1%, p ≤ 0.001). Elevated PAI-1 expression in DCMi-high subjects was associated with a diminished degree of cardiac fibrosis, decreased levels of TGF-β and reduced number of myofibroblasts. In addition, DCMi-high patients revealed an increased proportion of non-classical M2 macrophages towards classical M1 macrophages, indicating M2 macrophage-favoring properties of PAI-1 in inflammatory cardiomyopathies. Our findings give evidence that elevated expression of cardiac PAI-1 in subjects with high-grade DCMi suppresses fibrosis by inhibiting TGF-β and myofibroblast activation. Moreover, our data indicate that PAI-1 is involved in the polarization of M2 macrophages in the heart. Thus, PAI-1 could serve as a potential prognostic biomarker and as a possible therapeutic target in inflammatory cardiomyopathies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-020-00840-w. |
format | Online Article Text |
id | pubmed-7801308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78013082021-01-21 Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy Baumeier, Christian Escher, Felicitas Aleshcheva, Ganna Pietsch, Heiko Schultheiss, Heinz-Peter Basic Res Cardiol Original Contribution Plasminogen activator inhibitor-1 (PAI-1) has a cardioprotective function in mice by repressing cardiac fibrosis through TGF-β and plasminogen-mediated pathways. In addition it is known to be involved in the recruitment and polarization of monocytes/macrophages towards a M2 phenotype in cancer. Here, we investigated the expression of PAI-1 in human dilated cardiomyopathy (DCM) and inflammatory dilated cardiomyopathy (DCMi) and its effect on cardiac fibrosis and macrophage polarization. We retrospectively analyzed endomyocardial biopsies (EMBs) of patients with DCM or DCMi for PAI-1 expression by immunohistochemistry. Furthermore, EMBs were evaluated for the content of fibrotic tissue, number of activated myofibroblasts, TGF-β expression, as well as for M1 and M2 macrophages. Patients with high-grade DCMi (DCMi-high, CD3(+) lymphocytes > 30 cells/mm(2)) had significantly increased PAI-1 levels compared to DCM and low-grade DCMi patients (DCMi-low, CD3(+) lymphocytes = 14–30 cells/mm(2)) (15.5 ± 0.4% vs. 1.0 ± 0.1% and 4.0 ± 0.1%, p ≤ 0.001). Elevated PAI-1 expression in DCMi-high subjects was associated with a diminished degree of cardiac fibrosis, decreased levels of TGF-β and reduced number of myofibroblasts. In addition, DCMi-high patients revealed an increased proportion of non-classical M2 macrophages towards classical M1 macrophages, indicating M2 macrophage-favoring properties of PAI-1 in inflammatory cardiomyopathies. Our findings give evidence that elevated expression of cardiac PAI-1 in subjects with high-grade DCMi suppresses fibrosis by inhibiting TGF-β and myofibroblast activation. Moreover, our data indicate that PAI-1 is involved in the polarization of M2 macrophages in the heart. Thus, PAI-1 could serve as a potential prognostic biomarker and as a possible therapeutic target in inflammatory cardiomyopathies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-020-00840-w. Springer Berlin Heidelberg 2021-01-11 2021 /pmc/articles/PMC7801308/ /pubmed/33432417 http://dx.doi.org/10.1007/s00395-020-00840-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Contribution Baumeier, Christian Escher, Felicitas Aleshcheva, Ganna Pietsch, Heiko Schultheiss, Heinz-Peter Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy |
title | Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy |
title_full | Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy |
title_fullStr | Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy |
title_full_unstemmed | Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy |
title_short | Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy |
title_sort | plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes m2 macrophage polarization in inflammatory cardiomyopathy |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801308/ https://www.ncbi.nlm.nih.gov/pubmed/33432417 http://dx.doi.org/10.1007/s00395-020-00840-w |
work_keys_str_mv | AT baumeierchristian plasminogenactivatorinhibitor1reducescardiacfibrosisandpromotesm2macrophagepolarizationininflammatorycardiomyopathy AT escherfelicitas plasminogenactivatorinhibitor1reducescardiacfibrosisandpromotesm2macrophagepolarizationininflammatorycardiomyopathy AT aleshchevaganna plasminogenactivatorinhibitor1reducescardiacfibrosisandpromotesm2macrophagepolarizationininflammatorycardiomyopathy AT pietschheiko plasminogenactivatorinhibitor1reducescardiacfibrosisandpromotesm2macrophagepolarizationininflammatorycardiomyopathy AT schultheissheinzpeter plasminogenactivatorinhibitor1reducescardiacfibrosisandpromotesm2macrophagepolarizationininflammatorycardiomyopathy |